CLRB.US Cellectar Biosciences Inc

Healthcare Biotechnology USA Stocks
1.14 USD
Close of Nov 14, 2026
1.11 4.70
Market cap
USD 11.4M
P/E
-
P/B
0.52x
ROE
-122.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CLRB.US undervalued?

Graham number

The Graham number of Cellectar Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cellectar Biosciences Inc fundamental analysis

No fundamental analysis for Cellectar Biosciences Inc yet.

Cellectar Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple …

Full company profile